Targeting immune checkpoints in non small cell lung cancer
- PMID: 29525401
- DOI: 10.1016/j.coph.2018.02.006
"V体育官网入口" Targeting immune checkpoints in non small cell lung cancer
Abstract
Cancers have the ability to disrupt immune response by interfering with adaptive immunity. Blocking checkpoint pathways has become a target for pharmacological research in lung cancer with particular focus on peptides PD-1 and CTLA-4. A number of immune check-point inhibitors (ICIs) targeting both PD-1 and CTLA-4 pathways are under investigation within clinical trials, of which Nivolumab, Pembrolizumab and Atezolizumab have already been approved for lung cancer treatment by both FDA and EMA. Employed as single-agents in current practice for the treatment of advanced non-small cell lung cancer (NSCLC) ICIs have exhibited advantages in terms of overall survival and response rate with some responses being durable. Evaluating combinations of different inhibitors, dosing and sequencing within a multimodal therapy approach, together with better management of toxicity represents a new challenge for future research of therapy targeting immune check-points. VSports手机版.
Copyright © 2018 Elsevier Ltd V体育安卓版. All rights reserved. .
V体育ios版 - Publication types
"VSports手机版" MeSH terms
- VSports - Actions
- V体育官网入口 - Actions
- VSports app下载 - Actions
- Actions (V体育2025版)
- Actions (V体育官网入口)
- "V体育官网" Actions
- V体育官网入口 - Actions
- VSports在线直播 - Actions
- Actions (VSports)
- Actions (VSports在线直播)
- Actions (V体育官网)
- V体育官网入口 - Actions
Substances
- "VSports最新版本" Actions
- V体育2025版 - Actions
- VSports app下载 - Actions
LinkOut - more resources (V体育2025版)
Full Text Sources
Other Literature Sources
"V体育平台登录" Medical
VSports - Research Materials